摘要:Osiris公司宣布已完成多能成体干细胞新药Provacel^TM治疗心脏疾病的临床试验的病例入选,该试验目的在于评估Provacel^TM的安全性与初步疗效,Provacel^TM为成体干细胞的组成成分,可用于修复被损害的心脏。更为突出的是,Osiris公司的成体干细胞产品不要求特别配型。
注:因版权方要求,不能公开全文,如需全文,请咨询杂志社
热门期刊服务
Journal of Harbin Institute of Technology Journal of Semiconductors Journal of Beijing Institute of Technology Frontiers of Information Technology Electronic Engineering Journal of Computer Science and Technology World Journal of Gastroenterology China Petroleum Processing Petrochemical Technology Research in Astronomy and Astrophysics Communications in Theoretical Physics Transactions of Nonferrous Metals Society of China Journal of Systematics and Evolution Journal of Materials Science Technology相关文章
ospf协议